kidney disease glp 1 GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal Glucagon-Like Peptide-1 Receptor Agonist Use

Dietary changes are high yield, with about 50% of patients finding relief from gastrointestinal symptoms after adjusting intake, which highlights sugar alcohols and fermentable carbohydrates as frequent triggers

provides sodium, electrolytes, and a small amount of protein without requiring eating Avoid: fried foods, red meat, strong spices, heavily sauced dishes, and anything with a strong cooking smell on injection day

This makes it an easy way to support your skin, joints, gut health, and even hair and nails

doi:10.1006/geno.1996.4586 Rowlands J, Heng J, Newsholme P, Carlessi R

Emerging evidence suggests that GLP1 therapy can: Reduce hepatic fat content, as shown in MRI-PDFF studies Lower markers of liver inflammation and fibrosis Improve insulin sensitivity and metabolic control Although most trials focus on obese or diabetic populations, livercentric endpoints are increasingly evaluated, and benefits appear to extend beyond weight loss alone